

**In the Claims:<sup>1</sup>**

Please amend claims 1, 4 and 6 as follows:

1. (Currently amended) A pharmaceutical composition for reducing ~~influencing~~ angiogenesis, comprising

~~(a) — for positive regulation~~

~~— one or more bodies of~~

~~— CD66a, CD66a fragments or CD66a derived glycostructures, or CD66a ligands, ligand fragments or structures derived therefrom, as well as substances inducing the expression of CD66a or CD66a ligand,~~

~~or~~

~~(b) — for negative regulation~~

~~— one or more bodies of~~

~~— substances which inhibit the interaction between CD66a and CD66a ligands or~~

~~— substances which inhibit the expression of CD66a or CD66a ligand.~~

monoclonal anti-CD66a 4D1/C2 antibody which was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in an effective amount to reduce formation of capillaries by functionally blocking CD66a.

2. (Currently amended) The composition according to claim 1~~(b)~~, characterized in that the monoclonal anti-CD66a 4D1/C2 antibody ~~substances which functionally blocks CD66a binds~~ inhibit the interaction between CD66a and CD66a ligands are antibodies, proteins or peptides which bind specifically to one or more functional domains of CD66a ~~or its ligands~~.

3. (Cancelled)

4. (Cancelled)

<sup>1</sup> Consistent with the holding of Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., et al., 535 U.S. 722, 152 L.Ed.2d 944 (2002), decided May 28, 2002, any amendments herein that hereafter are deemed to be narrowing amendments by a court of competent jurisdiction in a final unappealed or unappealable decision, are not intended to relinquish any scope of equivalents unforeseeable at the time of this amendment or that relate to aspects of the invention having only a peripheral relation to the basis for the amendment.

5. (Withdrawn) The composition according to claim 1(b), characterized in that the substances which inhibit the expression of CD66a or CD66a ligand are anti-sense oligonucleotides or anti-sense RNA.
6. (Currently amended) The composition according to claim 4, ~~any of claims 1(b)-5~~, characterized in that it is capable of stopping tumor angiogenesis of lung cancer, breast cancer and colon carcinoma.
7. (Withdrawn) The composition according to claim 1(a), characterized in that the substances inducing the expression of CD66a or CD66a ligand are DNA coding for CD66a, Cd66a isoforms or CD66a fragments.
8. (New) A pharmaceutical composition for inhibiting *in vitro* angiogenesis, comprising monoclonal anti-CD66a 4D1/C2 antibody which was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in an effective amount to reduce formation of capillaries in cell cultures by functionally blocking CD66a.
9. (New) A method for inhibiting formation of capillaries comprising: introducing the composition of claim 1 into a tumor cell.
10. (New) A method for inhibiting formation of capillaries in cell cultures comprising: introducing the composition of claim 8 into a tumor cell.